Last reviewed · How we verify
JYNNEOS (Liquid Formulation)
JYNNEOS is a live attenuated vaccinia virus vaccine that stimulates immune responses against orthopoxviruses, including monkeypox and smallpox.
JYNNEOS is a live attenuated vaccinia virus vaccine that stimulates immune responses against orthopoxviruses, including monkeypox and smallpox. Used for Prevention of monkeypox (mpox) in adults at risk of exposure, Prevention of smallpox in at-risk populations.
At a glance
| Generic name | JYNNEOS (Liquid Formulation) |
|---|---|
| Also known as | Modified Vaccinia Ankara (MVA), MVA-BN, IMVAMUNE, IMVANEX |
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Live attenuated viral vaccine |
| Target | Orthopoxvirus antigens (vaccinia virus envelope and core proteins) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a modified vaccinia Ankara (MVA) virus strain that replicates poorly in human cells but triggers both cellular and humoral immune responses. This primes the immune system to recognize and respond to orthopoxvirus antigens, providing protection against monkeypox and smallpox infection through antibody and T-cell mediated immunity.
Approved indications
- Prevention of monkeypox (mpox) in adults at risk of exposure
- Prevention of smallpox in at-risk populations
Common side effects
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |